CN101019988B - 一种治疗糖尿病的中成药 - Google Patents
一种治疗糖尿病的中成药 Download PDFInfo
- Publication number
- CN101019988B CN101019988B CN200710064846A CN200710064846A CN101019988B CN 101019988 B CN101019988 B CN 101019988B CN 200710064846 A CN200710064846 A CN 200710064846A CN 200710064846 A CN200710064846 A CN 200710064846A CN 101019988 B CN101019988 B CN 101019988B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- diabetes
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 58
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 31
- 241000605447 Anemarrhena Species 0.000 claims abstract description 10
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 17
- 241000180649 Panax notoginseng Species 0.000 claims description 17
- 239000009636 Huang Qi Substances 0.000 claims description 14
- 239000008517 radix Trichosanthis Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- 241000219780 Pueraria Species 0.000 claims description 9
- 230000000694 effects Effects 0.000 abstract description 22
- 239000008280 blood Substances 0.000 abstract description 16
- 210000004369 blood Anatomy 0.000 abstract description 16
- 210000001124 body fluid Anatomy 0.000 abstract description 6
- 239000010839 body fluid Substances 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 240000006766 Cornus mas Species 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 241000218989 Trichosanthes Species 0.000 abstract 1
- 229930191283 anemarrhena Natural products 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 239000000796 flavoring agent Substances 0.000 description 13
- 235000019634 flavors Nutrition 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 235000009508 confectionery Nutrition 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 230000035922 thirst Effects 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 206010036067 polydipsia Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229940023488 pill Drugs 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000008967 Enuresis Diseases 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020741 Hyperpyrexia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 208000022329 Protein metabolism disease Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000006189 buccal tablet Substances 0.000 description 2
- 229940046011 buccal tablet Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003402 Arthropod sting Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018286 Gingival pain Diseases 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000003659 bee venom Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- -1 suspensoid Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗糖尿病的中成药，它以天花粉、桑白皮、知母、地骨皮和山茱萸等10余味中草药为原料。本发明具有清热泻火，生津润燥、益气降糖的功效。本发明是在传统的中医辨证治疗的基础上结合现代最新科研成果研制而成的。本发明的目的是提供一种治疗糖尿病的中成药，且具有疗效确切、安全方便、副作用小、价格低廉的特点。
Description
技术领域
本发明涉及一种治疗糖尿病的中成药，是一种治疗糖尿病以中草药为原料的中成药。属于中药领域。
背景技术
糖尿病是一种与遗传因素和多种环境因素相关联的以慢性高血糖为特征的代谢紊乱综合症。是由于体内胰岛素分泌或作用的缺陷，或两者同时存在而引起的糖、脂肪、蛋白质代谢紊乱。糖尿病一词描述了一种多病因的代谢疾病，特点是慢性高血糖，伴随因胰岛素分泌及(或)作用缺陷引起的糖、脂肪、蛋白质代谢紊乱。世界卫生组织在最近提出，糖尿病是由于多种病因引起的代谢紊乱，其特点是慢性高血糖。现代医学的糖尿病属中医学消渴病范畴。消渴病是因肺、胃、肾三脏燥热阴虚，水谷输布失常所致的口渴多饮，消谷善饥、尿频量多、或尿浊而有甜味、形体逐渐消瘦为主要特征的疾病。“三多一少”即多食、多饮、多尿、消瘦，是典型糖尿病病人的特征性临床表现。糖尿病是一种慢性终身性疾病，合理的综合治疗手段可以使病情得到良好的控制，并可防止或减缓慢性并发症的发生和发展。糖尿病的患病率在全球范围内呈逐渐增长趋势，尤其是在发展中国家，增长速度更快。现在全球糖尿病人约1.5亿，我国糖尿病人约2000万。糖尿病已成为全世界许多国家的常见病、多发病，其死亡率已居肿瘤、心血管病之后的第三位。
中医学认为糖尿病的发生主要与以下病因有关：1、素体阴虚，五脏虚弱。2、饮食不节，形体肥胖。3、精神刺激，情志失调。4、外感六淫，毒邪侵害。5、久服丹药，化燥伤津。6、长期饮酒，房事不节。因此糖尿病中医药治疗的基本原则是“辩证论治”。主要分为：1、燥热内盛型；2、脾虚湿滞型；3、肝郁气滞型；4、水湿停聚型；5、气血亏虚型；6、瘀血阻滞型；7、肾阳亏虚型；8、肾阴亏虚型；9、肝胆湿热型；10、湿热下注型。目前中药降糖作用慢，降糖作用持久，对改善患者临床症状，防治并发症方面疗效显著，提高患者的生存质量，延长寿命。
西医治疗本病的方法很多，但大多数只能达到近期临床效果，而不能制止复发，且存在不同程度的毒副作用。
发明内容
本发明是在传统的中医辨证治疗的基础上结合现代最新科研成果研制而成的。本发明的目的是提供一种治疗糖尿病的中成药，且具有疗效确切、安全方便、副作用小、价格低廉的特点。
本发明是由下述重量配比的原料制成的：
天花粉1.5～6份 桑白皮1.5～6份 知母1.0～4份
地骨皮2.5～10份 煅龙骨1.5～6份 当归0.1～2份
生黄芪1.5～6份 山茱萸0.1～2份 葛根1.0～4份
三七0.1～0.5份 淫羊藿0.1～2份 黄连0.1～2份
本发明的优选配方各原料的重量配比是：
天花粉2.5～3.5份 桑白皮2.5～3.5份 知母1.5～2.5份
地骨皮3.0～7.0份 煅龙骨2.5～3.5份 当归0.5～1.5份
生黄芪2.5～3.5份 山茱萸0.5～1.5份 葛根1.5～2.5份
三七0.2～0.4份 淫羊藿0.5～1.5份 黄连0.5～1.5份
本发明的最佳配方各原料的重量配比是：
天花粉 3份 桑白皮 3份 知母 2份
地骨皮 5份 煅龙骨 3份 当归 1份
生黄芪 3份 山茱萸 1份 葛根 2份
三七 0.3份 淫羊藿 1份 黄连 1份
本发明中的药物机理如下；
天花粉 性味甘、微苦，微寒。归肺、胃经。具有清热生津，润肺化痰，消肿排脓的功效。主治热病口渴，消渴多饮，肺热燥咳，疮疡肿毒等。(《中药大辞典》南京中医药大学 编著上海科学技术出版社 第二版 第443页)。
桑白皮 性味甘、辛，寒。归肺、脾经。具有泻肺平喘，利水消肿的功效。主治肺热或水饮停肺的胸满喘咳，咳血，水肿，脚气，小便不利等。(《中药大辞典》南京中医药大学 编著上海科学技术出版社 第二版 第2787页)。
知母 性味苦、甘、寒。归肺、胃、肾经。具有清热泻火，生津润燥的功效。可治疗外感热病、高热烦渴、结核病发热、肺热咳嗽、骨蒸潮热、内热消渴、肠燥便秘，小便不利、糖尿病等。(季宇彬主编《抗癌中药药理与应用》黑龙江科学技术出版社1999年版第817页)。
地骨皮 性味甘，寒。归肺、肾经。具有清虚热，泻肺火，凉血的功效。主治阴虚劳热，骨蒸盗汗，小儿疳积发热，肺热喘咳，吐血、衄血、尿血，消渴等。(《中药大辞典》南京中医药大学 编著上海科学技术出版社 第二版 第1141页)。
煅龙骨 性味涩、甘，平。归心、肝、肾、大肠经。具有镇心安神，平肝潜阳，收敛固涩的功效。主治心悸，怔忡，失眠，健忘，惊痫，颠狂，眩晕，自汗盗汗，遗精遗尿，崩漏带下，久泻久痢，溃疡久不收口及湿疮等。(《中药大辞典》南京中医药大学 编著上海科学技术出版社 第二版 第868页)。
当归 性味甘、辛、温。归肝、心、脾经。具有补血活血，调经止痛，润肠通便的功效。可用于血虚萎黄，眩晕心悸，月经不调，经闭通经，虚寒腹痛，肠燥便秘，风湿痹痛，跌打损伤，痈疽疮疡等。(季宇彬主编《抗癌中药药理与应用》黑龙江科学技术出版社1999年版 第553页)。
生黄芪 性味甘、温。归肺、脾经。具有益卫固表，利水消肿，托毒，生肌的功效。可治疗内伤劳倦、脾虚泄泻、脱肛、气虚血脱、崩带、自汗、盗汗、血痹、浮肿、痈疽不溃或溃之不敛及一切气衰血虚之症等。(季宇彬主编《抗癌中药药理与应用》黑龙江科学技术出版社1999年版 第1074页)。
山茱萸 性味酸、涩，微温。归肝、肾经。具有补益肝肾，涩精固脱的功效。可治疗眩晕耳鸣，腰膝酸痛，阳痿遗精，遗尿尿频，崩漏带下，大汗虚脱。内热消渴等。(国家药典委员会编《中华人民共和国药典》2000年版一部 第22页化学工业出版社)。
葛根 性味甘、辛，平。归脾、胃经。具有解肌发表，生津止渴，升阳止泻的功效。主治外感发热，头项强痛，麻疹初起、疹出不畅，瘟病口渴，消渴病，泄泻，痢疾等。(《中药大辞典》南京中医药大学编 著上海科学技术出版社 第二版 第3209页)。
三七 性味甘、微苦、温。归肝、胃、大肠经。具有散瘀止血，消肿定痛的功效。可治疗吐血、咳血、衄血、便血、血痢、崩漏、症瘕、产后血晕、恶露不下，外伤出血、胸腹刺痛、跌扑瘀血、痈肿疼痛、急性咽喉炎、头昏目眩、耳鸣、冠心病、心绞痛、急性坏死性节段小肠炎、蛇咬伤、蜂螫伤、风湿性关节炎病、高血压等。(季宇彬主编《抗癌中药药理与应用》黑龙江科学技术出版社1999年版 第60页)。
淫羊藿 性味辛、甘、温。归肝、肾经。具有补肾壮阳、祛风除湿、强筋骨的功效。可治疗阳痿不举、小便淋沥、筋骨挛急、半身不遂、腰膝无力、风湿痹痛、四肢不仁、更年期高血压症、神疲健忘、神经衰弱、骨髓炎等。(季宇彬主编《抗癌中药药理与应用》黑龙江科学技术出版社1999年版 第1143页)。
黄连 性味苦，寒。归心、肝、胃、大肠经。具有清热泻火，燥湿，解毒的功效。主治热病邪入心经之高热，烦躁，谵妄或热盛迫血妄行之吐衄，湿热胸痞，泄泻，痢疾，心火亢盛之心烦失眠，胃热呕吐，消谷善饥，肝火目赤肿痛，以及热毒疮疡，疔毒走黄，牙龈肿痛，口舌生疮，痔血，湿疹，烫伤等。(《中药大辞典》南京中医药大学 编著上海科学技术出版社 第二版 第2818页)。
本发明遵循中医“君臣佐使”的组方原则，用天花粉、桑白皮、知母、地骨皮和煅龙骨为君药，用生黄芪、当归、山茱萸、葛根和黄连为臣药，用三七和淫羊藿为佐使药。诸药相和共具清热泻火，生津润燥、益气降糖的功效，治疗糖尿病，具有疗效确切，无毒副作用，服用方便，价格低廉的特点。
本发明的中成药，在制备成药剂时可加入药物可接受的载体，所述药物可接受的载体可以是：淀粉、蔗糖、乳糖、甘露糖醇、硅衍生物、纤维素类及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、土温80、琼脂、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙、硬脂酸镁等。
本发明的中成药可以是任何可药用的剂型，这些剂型包括：片剂、糖衣片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、口含片、颗粒剂、丸剂、散剂、膏剂、丹剂、混悬剂、粉剂、溶液剂、注射剂、栓剂、软膏剂、硬膏剂、霜剂、喷雾剂、滴剂、贴剂。本发明的制剂，优选的中成药是口服剂型，如：片剂、胶囊剂、口服液、口含片、颗粒剂、丸剂、散剂、混悬剂、粉剂、溶液剂、滴剂、滴丸剂。更优选的中成药是胶囊剂、片剂、颗粒剂。
本发明药物临床使用结果表明，有如下优点：
1、本发明选用的中草药各组份符合中华人民共和国药品管理法之规定，利用各味中药的综合作用治疗糖尿病，对人体无毒无害。经动物急性毒性实验表明被实验的动物未见任何毒性反应，其主要脏器也无明显的改变，药物安全可靠。
2、本发明无须煎煮，无苦涩感，药中富含蛋白质，葡萄糖，葡萄糖醛酸，挥发油，果胶，果糖，有机酸，卵磷脂，维生素，氨基酸，还含皂甙，植物甾醇和钙等多种微量元素，利于人体吸收，增强体质，且服用方便。
3、本发明不仅可有效的治疗糖尿病，对糖尿病的预防也有很好的作用，大大提高了患者的生存质量，有较高的治愈康复效果。
糖尿病(消渴)疗效判定标准：(戴慎等主编《中医病证诊疗标准与方剂选用》人民卫生出版社 2001年版 第208页)。
1、治愈：症状消失，实验室检查多次正常。
2、好转：主要症状及实验室检查有改善。
3、未愈：症状及实验室检查无变化。
下面通过临床应用例进一步说明本发明药物对治疗糖尿病的治疗效果
经临床试验结果如下；治疗糖尿病患者45例。服用实施例1胶囊剂，每次2-10粒，每日三至四次，温开水送下，饭前半小时服用。一个月为一个疗程，连续服用三个疗程观察疗效。治愈26例占57.8％，好转18例占40％，未愈1例占2.2％，总有效率达97.8％。经三个疗程治疗后，患者口渴多饮，多食易饥，尿频量多，形体消瘦的症状明显改善。且病人无任何不良反应，三大常规化验及肝肾功能检测未发现异常。
具体实施方式
实施例1 胶囊剂 按下述重量称取原料：
天花粉 3份 桑白皮 3份 知母 2份
地骨皮 5份 煅龙骨 3份 当归 1份
生黄芪 3份 山茱萸 1份 葛根 2份
三七 0.3份 淫羊藿 1份 黄连 1份
制备方法是先取煅龙骨和三七干燥粉碎至120～200目细粉，再取天花粉、桑白皮、知母、地骨皮、当归、生黄芪、山茱萸、葛根、淫羊藿和黄连加水煎煮两次，第一次1.5～2小时，第二次0.5～1小时，合并两次煎液，滤过，滤液浓缩至80度～85度时，相对密度1.08～1.10的清膏，加入乙醇使清膏含醇量达70％，静置24小时，回收乙醇，在50度～55度时浓缩至相对密度1.30～1.32的清膏，再将清膏与煅龙骨和三七细粉混匀，干燥，粉碎成细粉，装入胶囊。每粒装0.3克，通常饭前半小时口服，温开水送下，一次2～10粒，一日三至四次，一个月为一个疗程。
实施例2 片剂 按下述重量称取原料：
天花粉 3份 桑白皮 3份 知母 2份
地骨皮 5份 煅龙骨 3份 当归 1份
生黄芪 3份 山茱萸 1份 葛根 2份
三七 0.3份 淫羊藿 1份 黄连 1份
制备方法是先取煅龙骨和三七干燥粉碎至120～200目细粉，再取天花粉、桑白皮、知母、地骨皮、当归、生黄芪、山茱萸、葛根、淫羊藿和黄连加水煎煮两次，第一次1.5～2小时，第二次0.5～1小时，合并两次煎液，滤过，滤液浓缩至80度～85度时，相对密度1.08～1.10的清膏，加入乙醇使清膏含醇量达70％，静置24小时，回收乙醇，在50度～55度时浓缩至相对密度1.30～1.32的清膏，再将清膏与煅龙骨和三七细粉混匀，干燥，粉碎成细粉，加入适量淀粉、乙醇制粒，干燥后，加入适量硬脂酸镁，压片，包糖衣即得。通常饭前半小时口服，温开水送下，一次2～10片，一日三至四次，一个月为一个疗程。
实施例3 颗粒剂 按下述重量称取原料：
天花粉 3份 桑白皮 3份 知母 2份
地骨皮 5份 煅龙骨 3份 当归 1份
生黄芪 3份 山茱萸 1份 葛根 2份
三七 0.3份 淫羊藿 1份 黄连 1份
制备方法是先取煅龙骨和三七干燥粉碎至120～200目细粉，再取天花粉、桑白皮、知母、地骨皮、当归、生黄芪、山茱萸、葛根、淫羊藿和黄连加水煎煮两次，第一次1.5～2小时，第二次0.5～1小时，合并两次煎液，滤过，滤液浓缩至80度～85度时，相对密度1.08～1.10的清膏，加入乙醇使清膏含醇量达70％，静置24小时，回收乙醇，在50度～55度时浓缩至相对密度1.30～1.32的清膏，再将清膏与煅龙骨和三七细粉混匀，干燥，粉碎成细粉，加入适量蔗糖和可溶性淀粉，乙醇制粒，干燥后装袋即得。通常饭前半小时温开水冲服，一次1～3袋，一日三至四次，一个月为一个疗程。
Claims (3)
1.一种治疗糖尿病的中成药，其中各原料药的重量配比是：
天花粉1.5～6份 桑白皮1.5～6份 知母1.0～4份
地骨皮2.5～10份 煅龙骨1.5～6份 当归0.1～2份
生黄芪1.5～6份 山茱萸0.1～2份 葛根1.0～4份
三七0.1～0.5份 淫羊藿0.1～2份 黄连0.1～2份。
2.根据权利要求1所述的一种治疗糖尿病的中成药，其中各原料药的重量配比是：
天花粉2.5～3.5份 桑白皮2.5～3.5份 知母1.5～2.5份
地骨皮3.0～7.0份 煅龙骨2.5～3.5份 当归0.5～1.5份
生黄芪2.5～3.5份 山茱萸0.5～1.5份 葛根1.5～2.5份
三七0.2～0.4份 淫羊藿0.5～1.5份 黄连0.5～1.5份。
3.根据权利要求1所述的一种治疗糖尿病的中成药，其中各原料药的重量配比是：
天花粉3份 桑白皮3份 知母2份
地骨皮5份 煅龙骨3份 当归1份
生黄芪3份 山茱萸1份 葛根2份
三七0.3份 淫羊藿1份 黄连1份。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710064846A CN101019988B (zh) | 2007-03-28 | 2007-03-28 | 一种治疗糖尿病的中成药 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710064846A CN101019988B (zh) | 2007-03-28 | 2007-03-28 | 一种治疗糖尿病的中成药 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101019988A CN101019988A (zh) | 2007-08-22 |
| CN101019988B true CN101019988B (zh) | 2010-05-19 |
Family
ID=38707914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710064846A Expired - Fee Related CN101019988B (zh) | 2007-03-28 | 2007-03-28 | 一种治疗糖尿病的中成药 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101019988B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114642721A (zh) * | 2022-04-24 | 2022-06-21 | 华裕(无锡)制药有限公司 | 一种治疗糖尿病的格列吡嗪片制剂及其制备方法 |
-
2007
- 2007-03-28 CN CN200710064846A patent/CN101019988B/zh not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| 王梅芳 |
| 王梅芳;竺叶青.中药及其复方制剂治疗Ⅱ型糖尿病的研究概况.中成药23 4.2001,23(4),281-284. * |
| 竺叶青.中药及其复方制剂治疗Ⅱ型糖尿病的研究概况.中成药23 4.2001,23(4),281-284. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101019988A (zh) | 2007-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101019985B (zh) | 一种治疗便秘的中成药 | |
| CN100571736C (zh) | 一种治疗习惯性流产的中药制剂 | |
| CN102366541B (zh) | 一种治疗消渴病的中药组合物 | |
| CN100431593C (zh) | 一种治疗脑积水的中药制剂 | |
| CN101897933B (zh) | 一种治疗白癜风的中成药 | |
| CN103251865A (zh) | 一种治疗腹泻的中药组合物 | |
| CN102423433A (zh) | 一种用于治疗银屑病的中药混合物 | |
| CN102406866A (zh) | 一种用于治疗银屑病的中药混合物 | |
| CN105232987A (zh) | 一种促进神经外科术后康复的中药 | |
| CN102579975B (zh) | 一种治疗银屑病的中药混合物 | |
| CN100431592C (zh) | 一种治疗前列腺增生的中药制剂 | |
| CN100431578C (zh) | 一种治疗前列腺增生的中药制剂 | |
| CN100450531C (zh) | 一种治疗小儿遗尿的中药制剂 | |
| CN101019988B (zh) | 一种治疗糖尿病的中成药 | |
| CN100415288C (zh) | 一种治疗银屑病的中药制剂 | |
| CN102406865A (zh) | 一种治疗银屑病的中药组合物 | |
| CN102406893A (zh) | 一种治疗银屑病的中成药 | |
| CN101028421B (zh) | 一种治疗慢性肾衰的中成药 | |
| CN100571725C (zh) | 一种治疗坐骨神经痛的中药制剂 | |
| CN101129832A (zh) | 一种治疗糖尿病尿路感染的中药组合物 | |
| CN100571764C (zh) | 一种治疗带状疱疹的中药汤剂 | |
| CN102423458A (zh) | 一种用于治疗银屑病的中成药 | |
| CN102362957B (zh) | 一种治疗深部红斑狼疮的中成药 | |
| CN102579895A (zh) | 一种治疗银屑病的中药组合物 | |
| CN100546607C (zh) | 一种治疗白癜风的中药制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING SINO-US INNOVATION INSTITUTE OF INTERNATIO Free format text: FORMER OWNER: BEIJING YIXINTANG MEDICINE INST. Effective date: 20110413 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 102300 NO. 2, YARD 191, DONGYANGTUO VILLAGE, JUNZHUANG TOWN, MENTOUGOU DISTRICT, BEIJING TO: 100076 NO. 10, EAST ALLEY 6, NORTH AREA, MINSHENG ROAD, VILLAGE 4, XIHONGMEN TOWN, DAXING DISTRICT, BEIJING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110413 Address after: 100076, No. six, No. 10, North East Road, Minsheng Road, fourth village, Xihongmen Town, Beijing, Daxing District Patentee after: Beijing Sino US Joint Institute of innovation and international difficult diseases Address before: Yang Tuo Cun 102300 Beijing city Mentougou District Jun Zhuang Zhen Dong Hospital No. 191 No. 2 Patentee before: Beijing YIxintang Medicine Institute |
|
| ASS | Succession or assignment of patent right |
Owner name: CHEN YUTANG Free format text: FORMER OWNER: BEIJING SINO-US INNOVATION INSTITUTE OF INTERNATIONAL STUBBORN DISEASES Effective date: 20120316 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| C56 | Change in the name or address of the patentee | ||
| CB03 | Change of inventor or designer information |
Inventor after: Chen Yutang Inventor before: Wang Xinsuo |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WANG XINSUO TO: CHEN YUTANG |
|
| CP02 | Change in the address of a patent holder |
Address after: 100076, Daxing District, Xihongmen, Beijing Town, four village, Minsheng Road, North East six, No. 10, Beijing Sino US joint innovation and International Institute of difficult diseases Patentee after: Chen Yutang Address before: 100076, Beijing Town, Daxing District Town, Xihongmen, four village, Minsheng Road, North East six, No. 10 Patentee before: Chen Yutang |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120316 Address after: 100076, Beijing Town, Daxing District Town, Xihongmen, four village, Minsheng Road, North East six, No. 10 Patentee after: Chen Yutang Address before: 100076, No. six, No. 10, North East Road, Minsheng Road, fourth village, Xihongmen Town, Beijing, Daxing District Patentee before: Beijing Sino US Joint Institute of innovation and international difficult diseases |
|
| ASS | Succession or assignment of patent right |
Owner name: BEIJING SINO-US JOINT INTERNATIONAL DISEASES RESEA Free format text: FORMER OWNER: CHEN YUTANG Effective date: 20120417 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20120417 Address after: 100076, Beijing Daxing District Xihongmen town fourth village Minsheng Road North East six 10, Beijing Sino US Joint Innovation Institute of international difficult disease Chen Zhonghua Dean Patentee after: Beijing Sino US Joint Institute of innovation and international difficult diseases Address before: 100076, Daxing District, Xihongmen, Beijing Town, four village, Minsheng Road, North East six, No. 10, Beijing Sino US joint innovation and International Institute of difficult diseases Patentee before: Chen Yutang |
|
| ASS | Succession or assignment of patent right |
Owner name: BEIJING SINO-US JOINT INTERNATIONAL DISEASES RESEA Effective date: 20121024 Owner name: BEIJING CHINESE AND FOREIGN INNOVATION INTERNATION Free format text: FORMER OWNER: BEIJING SINO-US JOINT INTERNATIONAL DISEASES RESEARCH INSTITUTE OF INNOVATION Effective date: 20121024 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100076 DAXING, BEIJING TO: 100012 CHAOYANG, BEIJING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20121024 Address after: 100012 Beijing city Chaoyang District Shangli Road No. 201 Beijing Chinese New International Medical Research Institute Patentee after: Beijing new China International Pharmaceutical Research Institute Patentee after: Beijing Sino US Joint Institute of innovation and international difficult diseases Address before: 100076, Beijing Daxing District Xihongmen town fourth village Minsheng Road North East six 10, Beijing Sino US Joint Innovation Institute of international difficult disease Chen Zhonghua Dean Patentee before: Beijing Sino US Joint Institute of innovation and international difficult diseases |
|
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: BEIJING SINA-AMERICA INNOVATION UNITED INTERNATIONAL DIFFICULT DISEASE RESEARCH INSTITUTE Effective date: 20121203 Owner name: BEIJING JINKUI CHINESE MEDICAL RESEARCH INSTITUTE Free format text: FORMER OWNER: BEIJING CHINESE AND FOREIGN XINCHUANG INTERNATIONAL MEDICAL RESEARCH INSTITUTE Effective date: 20121203 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Lin Wanshuo Inventor before: Chen Yutang |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100012 CHAOYANG, BEIJING TO: 100010 DONGCHENG, BEIJING Free format text: CORRECT: INVENTOR; FROM: CHEN YUTANG TO: LIN WANSHUO |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20121203 Address after: 100010, No. 3-1, building 3, Beijing Hutong, Dongcheng District, China Patentee after: Beijing Jingui Chinese Medicine Research Institute Co.,Ltd. Address before: 100012 Beijing city Chaoyang District Shangli Road No. 201 Beijing Chinese New International Medical Research Institute Patentee before: Beijing new China International Pharmaceutical Research Institute Patentee before: Beijing Sino US Joint Institute of innovation and international difficult diseases |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100519 Termination date: 20200328 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |